Geron Corporation

GERN

We are a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor, RYTELO (imetelstat), harnesses Nobel Prize winning science in a treatment that scientific evidence suggests reduces proliferation of malignant cells, allowing production of new healthy cells, which we believe drives differen…

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$691M

EPS-$0.11

P/E-9.77

P/FCF-6.04

EV/EBITDA-9.89

FCF Yield–

Div. Yield–

Net Debt/FCF1.6x

Geron Corporation intrinsic value

52-Week Range

$0.89$1.95

Profitability & Returns

TTM as of 2026-06 · YoY vs prior year · ROIC = NOPAT / invested capital

Revenue

N/A

Net Income (TTM)

-$68M

▲ +52.2% YoY

Op. Margin

–

ROIC

-11.60%

▲ +22.9pp YoY

Cash Flow & Balance Sheet

FCF = operating cash flow + capex · Net debt = total debt − cash · Balance sheet from latest filing

FCF (TTM)

-$114M

▲ +49.4% YoY

Op. Cash Flow (TTM)

-$114M

▲ +49.2% YoY

Net Debt

-$179M

Net Cash Position

Cash & Equiv.

$301M

5Y CAGR: -26.0%

Continue Research

Quality Scorecard

Is this a high-quality business?

Dividends

Payout safety and growth

Intrinsic Value

What is it worth?

Financials

Full income, cash flow, balance sheet

Peers

Pharmaceutical Preparations · Pick stocks to compare with GERN

CompareIntrinsic value

INVAInnoviva Inc.

$21.26+1.58%56

CNTACentessa Pharmaceuticals plc

No recent price10

IDYAIdeaya Biosciences Inc.

$32.36+3.29%40

SYRESpyre Therapeutics, Inc.

$99.24-0.03%10

PCRXPacira BioSciences Inc.

$36.40+0.03%58

HRMYHarmony Biosciences Holdings, Inc.

$34.42-7.04%82

LPCNLipocine Inc.

$1.44-1.37%40

VRTXVertex Pharmaceuticals Incorporated

$549.04+3.44%47

Held by ETFs

GERN is in 26 US ETFs. The largest of them, with GERN's weight in each:

Geron (GERN) in three numbers

Quality score: 10/100; Best check: net debt, -$179M. Weakest: return on capital, -11.6%.; Quality
Dividend: None; No dividend in the SEC filings we hold.; Dividends
P/E: -9.77; Negative: a loss over the last twelve months. Price to free cash flow -6.04.; Financials

Questions about Geron

Is Geron a high-quality business?

Geron scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is net debt at -$179M, and its weakest is return on capital at -11.6%. The Quality tab shows every check against its target.

Does Geron (GERN) pay a dividend?

No. Geron (GERN) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 31 Jul 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in GERN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing GERN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.